glp 1 receptor agonists canada Glucagon Like Peptide-1 (GLP-1) Agonist Market Report 2022 to 2030 Understanding GLP-1 receptor agonists and

Gigliotti, MS, RDN, CDCES, CSOWM

You may be a good candidate for GLP-1 treatment if you: Have been diagnosed with type 2 diabetes Have obesity, or a body mass index (BMI) of 30 or higher Have overweight (a BMI of 25 to 29.9) plus at least one weight-related condition, such as heart disease or type 2 diabetes Ultimately, the decision to start treatment for weight loss is up to you and your healthcare provider

[DOI] [PubMed] [Google Scholar] 294.Edfalk S., Steneberg P., Edlund H

In 2022, the FDA approved tirzepatide for the treatment of T2DM

doi: 10.1210/en.2014-1717

Dr Osama Hamdy is medical director of the obesity clinical programme at the Joslin Diabetes Center in Boston and assistant professor of medicine at Harvard Medical School